Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00341835 · ClinicalTrials.gov registry record
Genetic Epidemiology of Lung Cancer
A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 6,356
- Enrollment target
NCT00341835: Completed study, sponsored by National Human Genome Research Institute (NHGRI).
NCT00341835 is a clinical trial that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 6,356 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00341835 has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 6,356 participants
- Enrollment target
Study Summary
This study will search for genes that greatly increase the risk of developing lung cancer in conjunction with cigarette smoking or other environmental agents, or both. Lung cancer is the second most common cancer diagnosed among men and women and the leading cause of cancer death in the United States. It has been frequently given as an example of cancer determined only by the environment, certain occupations, and dietary habits. Yet researchers have long had a hypothesis that people vary in their risk of becoming affected when exposed to these factors. Also, some evidence has shown that lung cancer in families may be due to the combined effects of inheritance of a major gene and cigarette smoking. Individuals who have a confirmed diagnosis of lung cancer or a family history of lung cancer may be eligible to enroll their families in the study. Family members will be asked to do one or more of the following: * Complete a questionnaire about personal medical history, lifestyle, and diet. * Have blood drawn from a vein in the arm. * If a family member has had a biopsy or is scheduled for one, give permission to obtain medical records and a portion of the stored tissue. * If any relatives have died of cancer, sign a release form to allow researchers to get copies of medical and pathology records, and tissue samples from surgery. If the family members agree, they may be recontacted to answer questions about their health and those of their family, during an annual telephone conversation. Follow-up questionnaires may be sent to participants, to determine if any new cancers have developed in the family. In the event of a new cancer, the classification of the family may change from the low-risk to intermediate risk-level and from the intermediate-risk to high-risk level. Follow-up will continue, to get information about tumors and death. Also, a newsletter for lung cancer families will occasionally be distributed to participants. In the future, the Internet will also prov
Primary Outcome
Determine whether there are genetic variants contributing to lung cancer risk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,356 participants |
| Start Date | 2003-08-26 |
| Est. Completion | 2020-04-17 |
What the finished NCT00341835 record still lists
NCT00341835 is an observational study that tracks outcomes without assigning an intervention. Its 6,356 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00341835 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00341835 about?
NCT00341835 is a clinical study titled "Genetic Epidemiology of Lung Cancer". This study will search for genes that greatly increase the risk of developing lung cancer in conjunction with cigarette smoking or other environmental agents, or both. Lung cancer is the second most common cancer diagnosed among men and women and the leading cause of cancer death in the United State...
What is the current status of trial NCT00341835?
This trial is currently completed. The enrollment target is 6,356 participants. The study started on 2003-08-26. Estimated completion is 2020-04-17.
Who is sponsoring clinical trial NCT00341835?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04884802 · 6,254 participants · NA
The GUARDIAN Trial
- NCT03960099 · 6,250 participants · NA
Pictographs for Preventing Wrong-Patient Errors in NICUs
- NCT05440851 · 6,250 participants · NA
Platform of Randomized Adaptive Clinical Trials in Critical Illness
- NCT06566170 · 6,250 participants
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI